Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

This prospective, multicenter, single-arm, open-label Phase III study aimed to evaluate the efficacy and safety of Privigen® (10% liquid human intravenous immunoglobulin [IVIG], stabilized with l-proline) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Patients received on...

Descripción completa

Detalles Bibliográficos
Autores principales: Léger, Jean-Marc, De Bleecker, Jan L, Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Shebl, Amgad, Bauhofer, Artur, Zenker, Othmar, Merkies, Ingemar S J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2013
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910165/
https://www.ncbi.nlm.nih.gov/pubmed/23781960
http://dx.doi.org/10.1111/jns5.12017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910165/
https://www.ncbi.nlm.nih.gov/pubmed/23781960
http://dx.doi.org/10.1111/jns5.12017

Ejemplares similares